dc.contributor.author
Adey, Brett N.
dc.contributor.author
Cooper-Knock, Johnathan
dc.contributor.author
Al Khleifat, Ahmad
dc.contributor.author
Fogh, Isabella
dc.contributor.author
Damme, Philip van
dc.contributor.author
Corcia, Philippe
dc.contributor.author
Couratier, Philippe
dc.contributor.author
Hardiman, Orla
dc.contributor.author
Mclaughlin, Russell
dc.contributor.author
Gotkine, Marc
dc.contributor.author
Drory, Vivian
dc.contributor.author
Silani, Vincenzo
dc.contributor.author
Ticozzi, Nicola
dc.contributor.author
Veldink, Jan H.
dc.contributor.author
Berg, Leonard H. van den
dc.contributor.author
Carvalho, Mamede de
dc.contributor.author
Pinto, Susana
dc.contributor.author
Mora Pardina, Jesus S.
dc.contributor.author
Povedano Panades, Mónica
dc.contributor.author
Andersen, Peter M.
dc.contributor.author
Weber, Markus
dc.contributor.author
Başak, Nazli A.
dc.contributor.author
Shaw, Christopher E.
dc.contributor.author
Shaw, Pamela J.
dc.contributor.author
Morrison, Karen E.
dc.contributor.author
Landers, John E.
dc.contributor.author
Glass, Jonathan D.
dc.contributor.author
Vourc’h, Patrick
dc.contributor.author
Dobson, Richard J. B.
dc.contributor.author
Breen, Gerome
dc.contributor.author
Al Chalabi, Ammar
dc.contributor.author
Jones, Ashley R.
dc.contributor.author
Iacoangeli, Alfredo
dc.date.issued
2023-05-23T10:07:50Z
dc.date.issued
2023-05-23T10:07:50Z
dc.date.issued
2023-03-02
dc.date.issued
2023-04-17T10:35:33Z
dc.identifier
https://hdl.handle.net/2445/198345
dc.description.abstract
Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts.Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype.Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days.Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Reproducció del document publicat a: https://doi.org/10.3389/fncel.2023.1112405
dc.relation
Frontiers in Cellular Neuroscience, 2023, vol. 17
dc.relation
https://doi.org/10.3389/fncel.2023.1112405
dc.rights
cc by (c) Adey, Brett N. et al, 2023
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject
Esclerosi lateral amiotròfica
dc.subject
Marcadors genètics
dc.subject
Amyotrophic lateral sclerosis
dc.subject
Genetic markers
dc.title
Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion